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Urinary excretion of protectin (CDS9), complement SC5b-9 and cyto-
kines in membranous glomerulonephritis. Protectin (CD59) is a low
molecular weight glycophosphoinositol-anchored inhibitor of the mem-
brane attack complex of complement (MAC) that is present, for example,
on the membranes of endothelial cells and on epithelial cells of glomeruli
and distal tubull. To examine for the possibility that CD59 becomes
detached from cell surfaces following cell injury, this study evaluated renal
excretion of CD59 in patients with idiopathic membranous glomerulone-
phritis (MGN; N = 21), diabetic nephropathy (DNP; N = 15) and in
healthy control subjects (N = 13). CD59 in human urine was quantitated
by a competitive solid-phase radioimmunoassay having 13 kDa soluble
urinary CD59 as a standard. Immunofluorescence microscopy demon-
strated a decreased expression of CD59 in the glomeruli of MGN patients.
Using a Triton X-1 14 phase separation method 91 to 97% of urinary CD59
was found to be in a soluble form without anchor-associated phospholipid.
The mean (±sEM) level of urinary CD59 was 5.6 0.2 jrg/ml in MGN
patients, 3.7 0.4 sg/ml in healthy controls (P < 0.001) and 2.6 0.1 in
DNP patients (P < 0.001). When related to urinary creatinine (Ur) the
corresponding values were 11.9 5.6, 4.8 0.3 (P = 0.021) and 4.4 0.2
(P < 0.002), respectively. The amount of CD59 in urine correlated with
the urinary excretion of soluble terminal complement complexes, SC5b-9(r = 0.594, P < 0.006) in MGN patients. The excretion of CD59 also
correlated with the excretion of the inflammatory mediator IL-113 (r =
0.671, P 0.001) but not with TNF-n (r = 0.314, P = 0.178). No
correlation of CD59 excretion was observed with duration of the disease,
level of proteinuria, serum albumin concentration or serum creatinine
level. Based on these findings we speculate that the increased excretion of
CD59 into urine in MGN patients is due to complement activation and
inflammation induced shedding of CD59 from glomerular cells.
Protectin (CD59) is a glycophosphoinositol- (GPI-) anchored
inhibitor of the membrane attack complex (MAC) of complement
(C) [1—4]. CD59 inhibits C lysis by preventing C5b-8 catalyzed
polymerization of C9 on cell membranes [5, 6]. In human urine
CD59 is found in a soluble form [2, 7] that has an average
molecular mass of 13 kDa [8]. CD59 shows heterogeneity in the
structure of its oligosaccharide side chain linked to Asn-18 as well
as in the GPI-anchor linked to the C-terminal residue Asn-77 [8].
A major proportion of CD59 in the human urinary filtrate does
not have phospholipid attached to its GPI-anchor [8, 9]. Because
of its inability to incorporate into cell membranes the soluble
urinary CD59 is about 200-fold less active in inhibiting C lysis than
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the lipid-tailed form, although it retains its binding activity
towards the terminal C complexes (TCC) [7, 10].
Idiopathic membranous glomerulonephritis (MGN) in humans
is a clinically and morphologically variable disease [11, 12]. Kidney
biopsies of MGN patients usually show intraglomerular deposits
of MAC suggesting that the C system plays a pathophysiological
role in MGN. In Heymann nephritis (HN), the rat model for
human MGN, the primary targets for MAC-mediated damage are
the glomerular epithelial cells (GEC) [13—is]. In passive or active
HN antibodies against the autoantigenic gp330-complex become
deposited on the basement membranes and on GEC. Because of
immune complex formation and/or of surface alterations the C
system becomes activated resulting in formation of C5b-9 com-
plexes. On GEC the C5b-9 complexes seem to be engulfed in
intracellular vesicles and become transported through the epithe-
hal cells into the urinary space [14, 16].
The MAC inhibitor CD59 is expressed on both cultured human
GEC and on GEC in situ [17, 18]. The strongest expression of
CD59 in normal human renal cortex has been observed in
endothelial cells of intertubular capillaries, distal tubular epithe-
hal cells and in collecting ducts [18]. Comparison of CD59
expression in normal and diseased human kidneys has revealed an
increased expression of CD59 in the glomerular capillary walls of
SLE patients [19]. Recently we showed that cultured endothelial
cells are capable of up-regulating the level of CD59 mRNA and
protein expression upon treatment with inflammatory stimuli [20].
The measurement of urinary SC5b-9, a soluble form of the
terminal C complex, has been suggested to have clinical
importance in assessing the immunologic activity of MGN [21].
Patients with MGN, especially those with an unstable clinical
course, tend to secrete more soluble SC5b-9 complexes into
urine than healthy controls or patients with diabetic protein-
uria [12, 21—23]. In a study on acute myocardial infarction [24],
the deposition of MAC on cardiomyocytes was found to be
associated with a decreased expression of CD59 in the in-
farcted area. As CD59 may thus become shed from tissue
attacked by MAC we became interested in examining to what
extent CD59 is expressed in the kidneys and excreted into urine
in patients with MGN. To quantitate CD59 in urine a solid-
phase radioimmunoassay (RIA) was set up. Urinary levels of
CD59 were correlated with indicators of MGN activity (serum
creatinine, total urinary protein and albumin levels) and with
urinary excretion of SC5b-9. To see if urinary CD59 reflected
an ongoing inflammation in glomeruhi its levels were also
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correlated with urinary excretion of the inflammatory cytokines
IL-1/3 and TNF-a.
Methods
Purification of CD59 from urine
Urinary CD59 (Uc059) was purified from freshly voided urine
obtained from healthy laboratory personnel. The urine pooi that
contained protease inhibitors and sodium azide (0.02%) was
filtered through a BUchner funnel and a 0.22 j.rm pore size
Millipore filter (Bedford, MA, USA). After adjusting the pH to
7.4 the urine pooi was run through a YTI-153.1-Sepharose 4B
affinity column. YTH53.1 is a rat anti-CD59 mAb of the IgG2b
isotype (obtained from Prof. H. Waldmann, Dept. of Pathology,
University of Cambridge, UK). After a thorough washing of the
column the bound antigen was eluted with 0.1 M glycine buffer, pH
2.5, in 2 ml fractions into tubes containing 100 d of Tris buffer,
pH 9.0. The sample was pooled, concentrated and desalted with a
Sephadex G25 column (Pharmacia LKB, Uppsala, Sweden). The
total protein yield was approximately 2.0 mg of UCDS9 per one
liter of urine. In SDS-PAGE [25] under reducing conditions the
purified U9 gave a single band with an apparent Mr of 21 kDa.
In matrix assisted laser-desorption mass spectrometric analysis
UcD59 exhibited an average mass of 12,812 Da [8]. The protein
concentration of CD59 in a stock solution was determined by a
modified Lowry method [26]. One absorption unit at A280 corre-
sponded to 2.3 mg/ml of protein.
UCDS9 and lipid-tailed CD59 isolated from human heart
(CD5911) [24] were radiolabeled with 1251 to initial specific
activities of 106 to i07 cpm/g using the lodogen method (Pierce
Chemical Co., Rockford, IL, USA). CD59-depleted urine was
prepared by an overnight absorption of normal human urine with
the YTH53.1-Sepharose beads. The absence of CDS9 was verified
by CD59-RIA as described below.
Patients and samples
Urine samples of 21 MGN patients, 13 healthy controls (hos-
pital personnel) and 15 DNP patients were obtained from the
Fourth Department of Medicine, Helsinki University Central
Hospital. The mean (±sD) ages of patients, healthy control
subjects and DNP patients were 51.6 13.5, 40.2 8.2 and 44
3.6 years, respectively. The diagnosis of MGN was based on renal
biopsy. The duration of the disease (from diagnosis) ranged from
0 to 22 years. Patients were followed up for six months (after
obtaining the study samples) to observe the short-term clinical
course of MGN. Clinically progressive MGN was defined as: (a) a
rise in serum creatinine level by 25% above the normal level
(defined as 120 mol/liter) during follow-up in patients having
initially normal renal function; (b) 25% rise in serum creatinine
concentration in patients with initial renal failure (serum creati-
nine >120 jLmol/liter); or (c) renal failure at diagnosis responding
to i.v. corticosteroid therapy. These definitions required a mini-
mum of two consequtive serum creatinine analyses obtained at an
interval of at least two weeks. The median proteinuria in patients
was 3.1 (range, 0 to 17.4) g/24 hr and serum creatinine 102 (73 to
207) 1.tmol/liter. None of the patients used cytotoxic agents. One
patient used methylprednisolone at a dose of 20 mg every other
day. No other patient had used corticosteroids for at least six
months before the study. None had signs of an ongoing infection
or an additional inflammatory disease at the time of the study. Six
patients used inhibitors of the angiotensin convertase enzyme.
The median proteinuria of DNP controls was 5.4 (range 0.7 to 20)
g/24 hr and serum creatinine 169 (range 102 to 564) mol/liter.
Urine samples from both patients and controls were collected
from freshly voided morning urine. Urine samples were centri-
fuged at 2500 g for 10 minutes and supernatants were stored at
—20°C. Twenty-four-hour urine collection was used for analysis of
urinary protein excretion. Urinary protein concentrations were
determined by using the conventional biuret method. Blood
samples were taken by venipuncture into 10 mivi EDTA. Plasma
was separated within 30 minutes and stored at —70°C until
analyzed. Kidney biopsies were obtained from an additional group
of 5 recently diagnosed MGN patients. Control renal tissue
specimens were (N = 5) obtained from unaffected regions in
kidneys that were removed because of malignant renal tumors, All
specimens were frozen with isopentane (—70°C) cooled with
liquid nitrogen and stored at —70°C.
Quantitation of UCD5O by a competitive RIA
Wells of microtiter plates (Nunc-Immuno BreakApart Maxi-
sorp, Roskilde, Denmark) were coated with 100 i1 of the
YTH53.1 anti-CD59 mAb at 30 tg/ml in 0.1 M NaHCO3, pH 8.2.
Plates were incubated overnight at + 4°C. Next day the solution
was removed and wells were washed five times with 0.05% Tween
20/phosphate buffered saline (T-PBS). Three hundred i.tl of 3%
BSA in PBS was added to each well to block the nonspecific
binding sites and incubated for one hour at + 37°C, whereafter the
plates were washed five times with T-PBS. Varying amounts of
U59 (5 to 325 ng/50 d) diluted in CD59-depleted human urine
or PBS (50 1.d) were applied on wells as standards. Fifty sl
samples of urine diluted 1:2 or 1:5 in PBS were added into
individual wells. Immediately after application of samples, 50 tl
of '251-UcD59 (40,000 cpm) was added to each well and incubated
for 60 minutes at + 37°C. After washing the plates for five times
with T-PBS, individual wells were cut out and counted for
radioactivity in a gammacounter. The standard curve, B/B0 % vs.
CD59 (g/ml) was plotted after logarithmic transformation of the
x-axis values. B/B0 = 100% X (Standard — NSB)/(B1 — NSB),
where cpm values for standard samples (Standard), nonspecific
binding (NSB; wells not coated with antibody) and zero standard
(B0; standard without CD59) were taken into account. The levels
of CD59 in individual samples were interpolated from the stan-
dard curve. Intra- and interassay variations of the assay were
determined using standard specimens of human urine containing
low (0.4 .tg/ml), intermediate (1.5 g/ml) and high (6.5 g/ml)
concentrations of CD59. For analysis of interassay variation the
standard samples were stored at —20°C for various times (up to 5
months). Storage of the 21 MGN urine samples did not apprecia-
bly affect the CD59-RIA results, since analysis of the CD59 levels
on two occasions with an interval of two months yielded compa-
rable results (P = 0.855; paired Student's t-test). Similarly, no
significant change in CD59 level could be measured when BSA up
to a concentration of 30 g/liter was added to two urine samples
containing 2.0 or 6.6 jLg/ml of CD59.
Relative amounts of soluble and membrane forms of
CD59 in urine
A Triton X-114 (Tx-114) phase separation method [27] with
some modifications was used for the separation of soluble and
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membrane forms of CD59 in urine. Triton X-114 was added to
cell-free urine samples (800 jtl) of two MGN patients and to a
pool of urine samples from healthy donors at 0°C. Samples
containing 0.5% of Tx-114 were incubated at 37°C for three
minutes after which clouding occurred. The aqueous and deter-
gent phases were separated by centrifugation at 3000 g for three
minutes at 23°C. The aqueous phases were subjected to another
extraction with 0.5% Tx-114 after which the two detergent phases
were pooled. The amounts of CD59 in the aqueous and detergent
phases were quantitated by the CD59-RIA. For the quantitation
of CD59 in the detergent phase the RIA was performed by having
0.5% Tx-114 present in all assay buffers and in the standard
samples. The feasibility of the phase separation method was tested
by using '251-labeled UCD59 and CD59H [241 as controls for
soluble and membrane forms of CD59, respectively. '251-UcD59
and 1251-CD5911 (2 X i0 cpm) were added to separate urine
samples (800 l), whereafter two consecutive extractions with
Tx-i 14 were performed as described above. Finally, radioactivity
was counted both in the detergent and aqueous phases. To detect
if 0.5% Tx-i 14 had an effect on the results of the CD59-RIA,
cell-free urine samples of two MGN patients and a pooi of urine
samples from healthy donors were diluted in PBS or in PBS
containing 0.5% Tx-114 prior to the CD59-RIA analysis in the
absence or presence of 0.5% Tx-i 14, respectively.
Analysis of SC5b-9 in urine
A commercially available ELISA kit (Quidel Corp., La Jolla,
CA, USA) was used for the quantitation of SC5b-9 in urine. Urine
samples diluted in T-PBS were added to wells coated with a
mouse mAb against a neoepitope of human SC5b-9. After a one
hour incubation the wells were washed for five times and horse-
radish peroxidase-conjugated goat polyclonal antibodies to C6
and C7 were added. After another one hour incubation the wells
were washed for five times and a chromogen was added. Absor-
bance at 405 nm was measured after a 30 minute incubation at
+ 23°C. A standard curve for SC5b-9 (ng/ml) vs. absorbance was
generated using specimens with known amounts of SC5b-9. The
lower detection limit of the assay was 10 ng/ml. For statistical
analysis the values below this limit were arbitrarily assigned as 5
ng/ml.
Measurement of IL-1/3 and TNF-a
Urinary IL-lp was measured by RIA as follows: 100 d of
recombinant human IL-lp standards (Genzyme Corp., Boston,
MA, USA) and urine samples were incubated with 100 l of
polyclonal rabbit antiserum to human IL-113 (Endogen Inc.,
Boston, MA, USA) diluted 150-fold in PBS/1% BSA (pH 7.3) at
+23°C for four hours. Thereafter, 100 jd of tracer (1251-labeled
IL-113) diluted 2000-fold (°°10,000 cpm/100 jil) was added and
incubated for 16 hours at 4°C. Antibody-bound IL-I f3 was sepa-
rated by centrifugation after incubating (30 mm at + 23°C) the
mixtures with 1 ml of Micro Sepharose-anti-rabbit IgG (Pharma-
cia, Uppsala, Sweden). Radioactivities of the pellets were counted
and concentrations reported as means of duplicate estimations. A
solid-phase double-antibody RIA was used to analyze the concen-
trations of TNF-a in urine samples [28].
Isolation and immunostaining of urinary aggregates containing
lipid-tailed CD59
Membrane microparticles and/or molecular aggregates in the
urines of MGN patients and healthy donors were isolated by
ultracentrifugation (100,000 g, 30 mm) of cell-free urine samples.
The pellets were washed three times with PBS and incubated with
the Bric 229 mouse mAb (Bio-Products Laboratory, Bristol, UK)
against CD59. After washing the bound antibody was detected
with a fluorescein isothiocyanate (FITC)-conjugated antibody
against mouse immunoglobulins (Dakopatts, Glostrup, Den-
mark). Control stainings were performed by omitting the primary
antibody and by using an unrelated mouse mAb. After a final wash
the samples were applied on microscope slides which were
mounted with Mowiol [29] and examined on a Zeiss Standard
microscope equipped with a filter for fluorescein fluorescence.
Immunofluorescence analysis of CD59, C3 and C9 in kidneys
Frozen kidney specimens were sectioned in a cryostat (5 .tm)
and fixed with cold (— 20°C) acetone for five minutes. The sections
were incubated with the Bric 229 mouse anti-CD59 mAb, with a
polyclonal rabbit antibody against human C3c (Behringwerke AG,
Marburg, Germany) that recognizes the major activation frag-
ments of C3 (C3b, iC3b, and C3c) or with a polyclonal goat
antibody against human C9 (Quidel Corp., La Jolla, CA, USA). In
controls the primary antibodies were omitted. After washing the
sections were incubated with respective fluorescein isothiocya-
nate- (FITC-) conjugated secondary antibodies and processed for
immunofluorescence microscopy as described above.
Statistics
The two-tailed Student's t-test was used for analyzing differ-
ences between two individual groups when values had a normal
Gaussian distribution. Parametric data from three groups were
compared using one-way analysis of variance (ANOVA). Individ-
ual comparisons between two groups were performed by the
Mann-Whitney U test. When the values had a non-Gaussian
distribution data from three groups were analyzed by using the
Kruskal-Wallis analysis of variance followed by Mann-Whitney U
test for analysis of differences between two groups. To calculate
correlations and correlation coefficients (r) simple regression
analysis was used. When necessary the values were related to
urine creatinine levels (Ur) and natural logarithmic transforma-
tion was done to normalize the skewed distribution of the values.
Because of a low urinary creatinine value (40 mg/liter) in one
MON patient his CD59, SC5b-9, TNF-a and IL-1/3 values were
omitted from correlation analyses.
Results
Radioimmunoassay for CD59
Levels of CDS9 were quantitated by a solid-phase RIA with the
help of a standard curve prepared using purified soluble UcD59
(Fig. 1). The assay was setup to allow accurate detection of CD59
at concentrations of 0.1 jig/mi or higher. The intra-assay coeffi-
cients of variation were 13.2%, 12.1%, 8,1% for standards con-
taining low (0.4 jig/mi), intermediate (1.5 jig/mi) and high (6.5
jig/mI) concentrations of CD59, respectively. The interassay co-
efficients of variation were 15.5, 14.9 and 11.8%, respectively.
Paired t-test showed that there was no significant difference in
results whether the samples were diluted in PBS or CD59-
depleted urine (t = 1.248, P 0.226, N = 21).
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Fig. 1. A standard curve for the quantitation of soluble CD59 by a compet-
itive solid-phase RIA. Various amounts (0.1 to 6.6 rg/m1) of isolated U059
in PBS were subjected to the RIA. B/B0 indicates the relative amount of
bound 125I-U059 in the presence of varying concentrations of unlabeled
U059 (Methods). All points are means of duplicate determinations with
a coefficient of variation <14.5%.
Soluble versus lipid-tailed CD59 in urine
In our earlier studies we have observed that affinity-purified
UCD5O also contains a trace of lipid-tailed CD59 [8]. When
cell-free urine samples were ultracentrifuged for 30 minutes at
100,000 g the pellets were observed to contain immunoreactive
CD59 in small aggregates in indirect immunofluorecence analysis
(Fig. 2). Urinary cells from an MGN patient were also found to
express CD59 in a cluster-like fashion (Fig. 2D). The amounts of
soluble and lipid-tailed CD59 in urine were estimated with a
phase separation method using Triton X-1 14 (Tx-i 14) as a
detergent. In two random MON urine samples CD59 concentra-
tions (values corrected for dilution) were 0.18 and 0.24 rg/ml in
the detergent phases and 5.1 (96.6%) and 3.4 rg/mI (93.4%) in
the aqueous phases, respectively. The corresponding amounts in a
urine pooi from healthy donors were 0,2 j.g/ml in the detergent
phase and 2.0 jig/mI (90.9%) in the aqueous phase. In a control
experiment where '251-labeled UcD9 was added to a urine sample
97.6% of the radioactivity was found to partition with the aqueous
phase. For '251-CD59H the corresponding figure was 22.1%,
suggesting that a proportion of labeled CD59H was in a soluble
form.
To find out if detergent had any effect on the CD59-RIA
results, urine samples from two MGN patients and from a pool of
healthy donors were analyzed in the presence of 0.5% Tx-114 or
PBS. CD59 values (mean SEM, N = 4) in the two MGN samples
diluted in Tx-114 were 5.0 0.1 and 3.8 0.1 jig/mi. When the
same samples were diluted in PBS values 5.0 0.1 and 3.7 0.1
jig/mi were obtained. The corresponding values obtained in the
presence and absence of Tx-i14 for the pooled control sample
were 1.7 0.1 and 1.5 0.1 jig/mI.
Urinary excretion of CD59 and SC5b-9
Since it has been observed previously that MGN patients
excrete SC5b-9 complexes into urine and CD59 is a MAC
inhibitor we quantitated the amounts of SC5b-9 and CD59 in the
urines of MGN patients. The mean (±sEM) level of urinary CD59
was 5.6 0.2 jig/ml in MON patients (N = 21), which is
significantly higher than in healthy controls (3.7 0.4 jig/mi; N =
13; P < 0.001) or in DNP controls (2.6 0.1 jig/mI; N = 15; P <
0.001, ANOVA and Mann-Whitney U-test; Fig. 3A). Four of 21
patients showed clinically progressive MGN during a follow-up of
six months. For this group the mean (±sEM) level of urinary CD59
was 6.1 0.4 jig/mI. When the levels of CD59 were related to
urine creatinine concentrations the following mean (±sEM) values
were obtained: 11.9 5.6 jig/mg creatinine in the MGN patient
group (N = 21), 4.8 0.3 jig/mg creatinine in healthy controls (N
= 13; P = 0.021) and 4.4 0.2 jig/mg creatinine in DNP controls
(N = 15;P < 0.002, Mann-Whitney U-test; Fig. 3B). Prior analysis
of variance (KruskalWailis) indicated significant variance among
these three groups of values (P = 0.006). Creatinine corrected
CD59 values of healthy controls and DNP patients were not
significantly different (P = 0.090, Mann-Whitney U-test). To rule
out the potential influence of increased proteinuria on the excre-
tion of urinary CD59 we related CD59 levels of MGN and DNP
patients to urinary protein concentrations. In the MON group
CD59/protein values were 17.2 5.9 mg/g protein (N = 20) and
in the DNP group 1.0 0.3 mg/g protein (N = 15; P = 0.001,
Mann-Whitney U-test).
None of the healthy control subjects had detectable levels of
SC5b-9 in their urine specimens. Seventeen out of 21 MGN
patients excreted SC5b-9 complexes. The urinary SC5b-9 level in
these patients was 75 50 ng/mi (range 10 to 1070 ng/ml). The
highest SC5b-9 value (1070 ng/mi) was seen in patient no. 21, but
due to his low Ur level the Ur related value was omitted from
subsequent correlation analyses. As the distribution of SC5b-9
values was not Gaussian these values had to be treated as their
natural logarithms in correlation analyses. As shown in Figure 4
the urinary level of CD59 correlated with the urinary excretion of
SC5b-9 in the MGN patients. In contrast, the urinary CD59 values
did not correlate with serum creatinine level (r = 0.342, P
0.140), serum albumin concentration, urinary protein concentra-
tion (Fig. 5) or duration of the disease.
Urinary levels of CD59 and cytokines
The mean (±sEM) value of urinary IL-113 was elevated in MGN
patients as compared with the controls: 403 48 pg/mg creatinine
versus 172 27 pg/mg creatinine (healthy controls; P < 0.001)
and 39.9 3.0 pg/mg creatinine (DNP controls; P < 0.001,
Kruskal-Wallis and Mann-Whitney U-test), respectively. The ex-
cretion of urinary CD59 in MGN patients correlated strongly with
the excretion of IL-lp (r = 0.671, P = 0.001; Fig. 6A). A similar
correlation appeared to exist in the healthy control group (r =
0.745, P = 0.003; Fig. 6A). This correlation was, however, driven
by a single outlier point and disappeared when this point was
omitted (r = 0.179, P = 0.369). No correlation between urinary
CD59 and IL-1/3 was seen in the DNP group (r = 0.307, P =
0.265). The urinary excretion of TNF-co was also higher in MON
patients than in controls: 37.2 2.6 versus 13.5 1.5 pg/mg
creatinine (healthy controls; P < 0.001) and 18.3 3.0 pg/mg
creatinine (DNP controls; P < 0.001, ANOVA and Mann-
Whitney U-test), but did not correlate with the excretion of CD59
in any of the three groups (Fig. 6B).
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Fig. 2. Demonstration of the presence of CD59 in urina,y aggregates and cells by immunofluoresence microscopy. Urinary aggregates were isolated by
ultracentrifugation from cell-free urine samples of an MGN patient (A) and a healthy control subject (B) and stained for CD59 with the BRIC 229
anti-CD59 antibody. A control sample stained with an unrelated mouse mAb fails to show a positive reaction (C). D. Staining of urinary epithelial cells
from an MGN patient for CD59 with the BRIC 229 niAb (A—C, magnification 500X; D, 120X; inset, 300X).
Expression of CD59 in MGN kidney biopsy specimens
Renal expression of CD59 was investigated in four patients
belonging to the MGN group of this study and in one MGN
patient outside this group. Biopsies were taken during the active
phase of the disease. Five control cases had no known glomerular
disease. Active glomerular involvement in MGN was indicated by
strong, diffuse and granular deposits of C3 activation products and
C9 in the MGN glomeruli (Fig. 7 B, D). As shown in Figure 7A
and C, the expression of CD59 was decreased in the glomerular
capillaries and podocytes of MGN patients as compared with the
controls (E). The expression of CD59 in the glomeruli of MGN
patients was usually not homogeneous, as parts of glomeruli
appeared almost negative for CD59. No significant differences in
the CD59 expression pattern were observed among the five MGN
cases studied.
Discussion
In the present study we have quantitated for the first time levels
of CD59 in the urines of MGN patients and control subjects using
a competitive solid-phase radioimmunoassay. The RIA proved to
be reproducible and sufficiently sensitive for the measurement of
CD59 in both normal and pathological urine samples. MGN
patients were observed to excrete significantly higher amounts of
CD59 into their urines than healthy control subjects or patients
with diabetic nephropathy. Because of the limited number of
individuals included in this study we cannot rule out the possibility
that urinary excretion of CD59 correlates with disease activity. In
accordance with a suspected intraglomerular complement mem-
brane attack in MGN the increased urinary excretion of CD59
correlated with an increased excretion of soluble terminal SC5b-9
complement complexes and of the cytokine IL-1/3. Immunofiuo-
rescence analysis of biopsies of MGN patients showed a decreased
expression of CD59 along with deposits of C9 in the glomeruli of
MON patients.
CD59 in human urine may originate from kidneys or plasma. In
human kidneys CD59 has been localized to glomerular and distal
tubular epithelial cells and to capillary endothelia [17, 18]. Mono
Q anion exchange chromatography analysis of urinary CD59 has
shown that it is composed of at least 8 to 10 different structural
(mainly glycosylation) variants, that include forms with a lipid-tail
[8]. This observation was confirmed in the present study, where
9.1% of CD59 in a urine pool from healthy donors partitioned
into the Triton X-1 14 detergent phase. In two MGN patients the
corresponding values were 3.4 and 6.6%, indicating that more
than 90% of urinary CD59 represented a soluble isoform. Control
experiments with '251-labeled UCDS9 and CD5911 showed that the
:
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Fig. 4. Correlation between urinacy excretion of CD59 and soluble tenninal
complement complexes (SC5b-9) in MGN patients. CD59 levels were
measured by RIA and SC5b-9 levels by ELISA. To allow correlation
analysis the CD59 and SC5b-9 values relative to urine creatinine levels are
expressed as their natural logarithms. Correlation coefficient (r) was
calculated by regression analysis. The point in parentheses represents
values obtained from the urine analysis of patient no. 21 with an
exceptionally low U. level. r value without this point is 0.594 (P < 0.006)
and r = 0.879 (P < 0.001) if the point is included. Closed triangles indicate
values from patients with progressive MGN.
Men [241 suggested that in an infarcted area of human heart a
proportion of CD59 was present in small vesicles outside myocar-
dial cells. In light of this observation it appears possible that in
urine the phospholipid-tailed CD59 could have become shed from
glomerular or tubular cells within micelles or small vesicle-like
membrane microparticles. In support of this interpretation, im-
munofluorescence microscopy analysis demonstrated CD59 in
small aggregates or vesicles in the ultracentrifugation pellet ofI
Healthy MGN DNP
controls
urine samples. It is likely that CD59 in these aggregates represents
lipid-tailed urinaly CD59. Decreased expression of CD59in the
Fig. 3. Urinary levels of CD59 in MGN and DI'IP patients and healthy
controls. CD59 concentrations are shown as raw values (A) or corrected
for urinary creatinine (B). CD59 concentrations were quantitated by RIA
in urine samples from healthy control subjects (0), patients with MGN
glomeruli of MGN patients (Fig. 7) further suggests that a
proportion of CD59 has become detached from the glomerular
.
epltileLlai or capisiary enuotneilai cells.
Using matrix-assisted laser mass spectrometric analysis we have
(•), progressive MGN (A) or DNP patients (0). Bars indicate mean recently demonstrated that soluble UCDS9 lacks the diacyl glycerol
values in the control and patient groups. 3-phosphate part of the glycolipid anchor [8]. The fact that over
90% of urinary CD59 is without a lipid-tail implies that the
phospholipid has become cleaved off from the molecule. The
Triton X-114 partitioning method can be used for the separation candidate enzyme for doing the cleavage is phospholipase D
of soluble and lipid-tailed CD59. After two detergent extractions (PIPLD) since the cleavage site is between the myoinositol and
97.6% of 1251-UCDSO remained in the aqueous phase. The unex- phosphate of the GPI-anchor [8, 91. As PIPLD cannot cleave
pectedly high figure (22.1%) for 1251-CD5911 remaining in the intact molecules on cell membranes a prerequisite is that the
aqueous phase is unlikely to be due to incomplete partitioning, GPI-anchored molecules have become shed from the cell mem-
but probably reflects partial loss of the phospholipid-tail from the branes. Thus a possible source of soluble urinary CD59 are
molecule prior to tissue processing or during the purification, glomerular and/or tubular cells, from where CD59 has become
radiolabeling or storage of CD59H. Whether the urine samples shed and subsequently cleaved by PIPLD. Alternatively, the
were diluted in PBS with or without 0.5% Triton X-l 14 was not soluble form of CD59 may have become filtered from blood
observed to have any significant effect on the CD59-RIA results. plasma, where an extracellular form of PIPLD has been found
A recent immunofluorescence study by Väkevä, Laurila and [30]. As a small 13 kDa molecule the soluble, hydrophilic CD59,
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CD59, jig/mi
S
Fig. 5. Correlation analysis between urinaiy CD59 and protein levels in
MGN and DNP patients. Urinaiy CD59 concentrations were determined
by RIA in MGN patients without (•) or with (A) progressive disease and
in DNP patients (LI). MGN: r = 0.168, P = 0.467; DNP: r 0.228; P
0.4 14.
unlike the hydrophobic membrane form, would become easily
filtered through glomeruli and explain its low levels in normal
plasma [31]. Although one cannot exclude the possibility that
plasma levels of soluble CD59 are increased in MGN, a compar-
ison between the MGN and DNP groups and lack of correlation
between CD59 excretion and proteinuria both suggest that the
increased CD59 excretion in MGN is not simply due to a change
in glomerular permeability or proteinuria.
Increased urinary levels of CD59 were found to be accompa-
nied by an increased urinary excretion of SC5b-9 complexes in
MGN patients. In previous studies increased levels of C3dg and
SC5b-9 complexes in urine have been shown to indicate disease
activity in MGN [12]. Also, patients with IgA nephropathy, focal
glomerulosclerosis or diabetic glomerulosclerosis have been
shown to excrete SC5b-9 complexes into urine [23, 321. Although
a proportion of SC5b-9 complex formation in urine is due to the
proteinuria itself, the high levels of urinary SC5b-9 complexes in
MGN patients are not explained by proteinuria alone [22]. The
fact that the excretion of U9 in MGN patients correlated with
the excretion of SC5b-9 suggests that the complement membrane
attack complex could lead to an increased shedding of CD59 from
the glomerular (or tubular) cells. Release of CD59 could lead to
the observed partial loss of CD59 expression in glomeruli and
sensitization of glomerular cells to further attacks by the MAC.
Both human and rat glomerular mesangial cells have been
shown to respond to a MAC attack in vitro by producing a number
of mediators of inflammation: IL-i, TNF-a, oxygen radicals and
eicosanoids [33—35]. Rat glomerular epithelial cells have been
reported to synthesize prostaglandin E and thromboxane B2 [35].
Concomitant increases in TCC formation, urinary cytokine levels
and in the excretion of UCD59 in the present study are compatible
with an ongoing complement membrane attack within the glomer-
0
A Li SSi #5•S
LI IJRAS
Lb o"
o 09.,
LI
uli of MGN patients. Glomerular cell injury does not exclude
other sources of IL-1/3 in the kidneys since MGN is often
associated with tubular injury and interstitial inflammation. At
present, however, it is difficult to estimate the relative contribu-
tion of, for example, migrating mononuclear phagocytes as a
source of urinary IL-113 in MGN. The initial inducers of C
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Fig. 6. Correlation between urinaiy excretion of UcD5S and cytokines. Urine
levels of CD59, IL-1/3 and TNF-a were quantitated by RIA. Correlations
(r) of CD59 concentrations with those of IL-i /3 (A) and TNF-cs (B) in
MGN (5) or DNP (LI) patients and healthy control subjects (HC; 0) were
calculated by simple regression analysis. Patients with progressive MGN
(A). In A, MGN, r = 0.671; P = 0.001; HC, r = 0.745,P = 0.003; DNP,
r = 0.307; P = 0,265. In B, MGN, r = 0.314, P = 0.178; HC, r 0.167, P
= 0.585; DNP, r = 0.073, P = 0.795.
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Fig. 7. Immunofluorescence analysis of CD59, C3 and C9 in MGN kidneys. Kidney specimens from MGN patients (A, B, C, D) or from unaffected parts
of control kidneys removed because of renal carcinoma (E, F) were fixed with acetone and immunostained for CD59 with the Eric 229 mAb (A, C, E),
or with polyclonal antibodies against C3c (B) or C9 (D, F). Note decreased and inhomogeneous staining for CD59 and strong staining for C3c and C9
in the glomeruli of MGN patients.
activation and cytokine production in human MGN remain un- membrane attack or other inflammatory signals by first increasing
known, but the C5b-9 complex is likely to mediate stimulation, the expression and shedding of CD59 [20]. Upon persistent MAC
and perhaps damage, of the affected cells. To prevent further attacks the net balance may shift towards loss of CD59 from the
damage the glomerular cells may respond to the complement glomerular cells, as observed in the biopsy specimens. The initial
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stimulatory effect of MAC or other signals may explain why in a
previous study a qualitative increase in glomerular expression of
CD59 was observed in SLE patients with glomerulonephritis [19].
Taken together, our results support a model where the terminal
C complexes become formed and stimulate local cytokine produc-
tion in the glomeruli of MGN patients. Increased shedding of
CD59 into urines of MGN patients may be the consequence of
both cytokine-induced inflammation and MAC-mediated cell
damage.
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